Recombinant Human Angiotensin-converting enzyme 2 (ACE2), partial (Active)

SKU: QP15108
Species: Human
Applications: WB, ELISA, and others.
Available Tags: Mammalian cell
Available Hosts: hFc1
Purity: Greater than 90% as determined by SDS-PAGE.
Length (Amino Acids): 18-740aa

This product is currently out of stock and unavailable.

SKU: QP15108 Category:
 PDF Datasheet
AT1:AU2 n

QP15108, ACE2 Recombinant Protein Product Attributes

n

Product Type: Recombinant Protein

n

Recombinant ACE2 based upon sequence from Homo sapiens (Human)

nn

Host: QP15108 protein expressed in Mammalian cell.

n

Available Tags: C-terminal hFc1-tagged

n

Protein Construction: A cDNA sequence encoding the sequence of ACE2 was constructred and used to recombinantly synthesize the protein.

n

Recommended Applications: Western Blot, ELISA and others

n

Application Notes: Please contact us for application specific information for QP15108.

n

Bioactivity Data: ①Measured by ACE2 protein (CSB-MP866317HU) binding ability in a functional ELISA. Coat the plate with 0.2ug/well (2ug/ml, 100ul/well) of SARS-CoV-2 S1 protein (CSB-MP3324GMY), add 100ul/well (0.7629-100000ng/ml, gradient dilution, 2x to 18x) of ACE2 protein and 100ul/well of Peroxidase-Affinipure Goat Anti-Human IgG, Fcγ Fragment Specific (CSB-PA160506). Wells were washed with buffer, and then A450 nm was measured. The results showed SARS-CoV-2 S1 protein could bind ACE2 protein. The EC50 is 56.64 – 103.6 ng/ml. ②Measured by ACE2 protein (CSB-MP866317HU) binding ability in a functional ELISA. Coat the plate with 0.5ug/well (5ug/ml, 100ul/well) of SARS-CoV-2 S1-RBD protein (CSB-YP3324GMY1), add 100ul/well (0.762939-100000ng/ml, gradient dilution, 2x to 18x) of ACE2 protein and 100ul/well of Peroxidase-Affinipure Goat Anti-Human IgG, Fcγ Fragment Specific (CSB-PA160506). Wells were washed with buffer, and then A450 nm was measured. The results showed SARS-CoV-2 S1-RBD protein could bind ACE2 protein. The EC50 is 31.80 – 44.69 ng/ml. ③Measured by ACE2 protein (CSB-MP866317HU) binding ability in a functional ELISA. Coat the plate with 0.5ug/well (5ug/ml, 100ul/well) of SARS-CoV-2 S1-RBD protein (CSB-MP3324GMY1b1), add 100ul/well (0.762939-100000ng/ml, gradient dilution, 2x to 18x) of ACE2 protein and 100ul/well of Peroxidase-Affinipure Goat Anti-Human IgG, Fcγ Fragment Specific (CSB-PA160506). Wells were washed with buffer, and then A450 nm was measured. The results showed SARS-CoV-2 S1-RBD protein could bind ACE2 protein. The EC50 is 2.785-9.139 ng/ml. ④Measured by ACE2 protein (CSB-MP866317HU) binding ability in a functional ELISA. Coat the plate with 0.2ug/well (2ug/ml, 100ul/well) of ACE2 protein, add 100ul/well (0.00001164153-200000ng/ml, gradient dilution, 4x to 18x) of SARS-CoV-2 S1-RBD protein (CSB-MP3324GMY1) and 100ul/well of Peroxidase-Affinipure Goat Anti-Human IgG, Fcγ Fragment Specific (CSB-PA160506). Wells were washed with buffer, and then A450 nm was measured. The results showed SARS-CoV-2 S1-RBD protein could bind ACE2 protein. The EC50 is 8.363-12.82 ng/ml ng/ml. ⑤The SPR sensorgram shows the binding between ACE2 protein (CSB-MP866317HU) and SARS-CoV-2 S1-RBD protein (CSB-YP3324GMY1). ACE2 protein was injected at 5 concentrations (400, 200, 100, 50, 0 nM) across 0.5 mg/ml of SARS-CoV-2 S1-RBD protein captured on a COOH chip. The results showed ACE2 protein could bind SARS-CoV-2 S1-RBD protein with an affinity constant of 100 nM. ⑥The SPR sensorgram shows the binding between ACE2 protein (CSB-MP866317HU) and SARS-CoV-2 S1-RBD protein (CSB-MP3324GMY1b1). ACE2 protein was injected at 5 concentrations (100, 50, 25, 12.5, 0 nM) across 0.5 mg/ml of SARS-CoV-2 S1-RBD protein captured on a COOH chip. The results showed ACE2 protein could bind SARS-CoV-2 S1-RBD protein with an affinity constant of 13.8 nM.

n n nn

Amino Acid Sequence: QSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVS

n

Purity: Greater than 90% as determined by SDS-PAGE.

n

Reconstitution Instructions: See COA, sent with protein.

nn

Endotoxin Levels: Less than 1.0 EU/ug as determined by LAL method.

n

Buffer: Lyophilized from a 0.2 um sterile filtered PBS, 6% Trehalose, pH 7.4

n

Storage Conditions: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

n

Physical Appearance: White powder.

n n n

n

n

Limitations and Performance Guarantee

n

enQuire Bio’s products are guaranteed and approved for RESEARCH USE ONLY or manufacturing purposes. This product may not be used as a pharmaceutical agent, or other product intended for human consumption without meeting additional regulatory requirements. This product is guaranteed to work for a period of two years when stored at -70C or colder, and one year when aliquoted and stored at -20C.

n

Recombinant Human Angiotensin-converting enzyme 2 (ACE2), partial (Active)